Methotrexate monotherapy (number of patients = 522, number of visits = 1090)
|
MTX dose group PS-adjusted
|
0.070 (−0.15; 0.29)
|
0.12 (−0.19; 0.43)
|
0.060 (−0.09; 0.21
|
MTX dose group unadjusted
|
−0.63 (−0.79; −0.47)
|
−0.90 (−0.13; −0.67)
|
0.16 (0.055; 0.26)
|
Methotrexate + csDMARDs (number of patients = 262, number of visits = 567)
|
MTX dose group PS-adjusted
|
0.051 (−0.23; 0.33)
|
0.024 (−0.37; 0.42)
|
−0.0058 (−0.20; 0.19)
|
MTX dose group unadjusted
|
−0.18 (−0.44; 0.072)
|
−0.28 (−0.63; 0.072)
|
0.092 (−0.085; 0.27)
|
Methotrexate + oral glucocorticoid (+/−csDMARDs) (number of patients = 615, number of visits = 1403)
|
MTX dose group PS-adjusted
|
−0.047 (−0.26; 0.16)
|
−0.16 (−0.44; 0.12)
|
−0.028 (−0.16; 0.11)
|
MTX dose group unadjusted
|
−0.42 (−0.56; 0.28)
|
−0.74 (−0.93; −0.55)
|
0.13 (0.045; 0.22)
|